Pfizer Inc. (NYSE:PFE) Shares Sold by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 85.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,848 shares of the biopharmaceutical company’s stock after selling 45,562 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Pfizer were worth $218,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Clifford Swan Investment Counsel LLC boosted its holdings in Pfizer by 4.7% in the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after acquiring an additional 18,611 shares during the last quarter. LifePlan Financial LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $255,000. Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in shares of Pfizer during the 4th quarter worth about $16,166,000. KLCM Advisors Inc. increased its position in Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after purchasing an additional 74,487 shares in the last quarter. Finally, Farmers Trust Co. raised its holdings in Pfizer by 2.0% in the fourth quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after buying an additional 4,410 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.4 %

Shares of NYSE:PFE traded down $0.11 during midday trading on Wednesday, reaching $27.72. The company had a trading volume of 5,073,509 shares, compared to its average volume of 40,362,035. The stock has a market capitalization of $157.08 billion, a P/E ratio of -462.33, a PEG ratio of 1.10 and a beta of 0.69. The stock’s fifty day moving average price is $27.96 and its 200-day moving average price is $27.71. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.23 EPS. Equities research analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a dividend yield of 6.06%. Pfizer’s payout ratio is -2,800.00%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on PFE shares. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, June 26th. Morgan Stanley upped their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $35.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.